Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 937.61 +34.13 (+3.78%) Streaming Delayed Price Updated: 4:00 PM EDT, May 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Regeneron Pharmaceuticals < Previous 1 2 3 4 5 Next > Regeneron Reports First Quarter 2024 Financial and Operating Results May 02, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases April 29, 2024 Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and... From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases April 25, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in Friday Morning Trading March 22, 2024 Via Investor Brand Network Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is a Leading Gainer in 2/20 Morning Trading February 20, 2024 Via Investor Brand Network Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO April 24, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT) April 22, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN) April 18, 2024 From Kirby McInerney LLP Via GlobeNewswire REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Regeneron Stockholders and Encourages Investors to Contact the Firm April 17, 2024 From Bragar Eagel & Squire Via GlobeNewswire The Law Offices of Frank R. Cruz Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors April 17, 2024 From Law Offices of Frank R. Cruz Via Business Wire INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm April 11, 2024 From Schall Law Via GlobeNewswire Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma April 07, 2024 Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024 April 01, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Provides Update on Biologics License Application for Odronextamab March 25, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization March 12, 2024 $250,000 top award goes to Achyuta Rajaram in the nation’s oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol March 11, 2024 Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH) From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet March 08, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation February 23, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review February 21, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU) February 16, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces Investor Conference Presentations February 06, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results February 02, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma February 02, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs January 30, 2024 Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) January 25, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards January 24, 2024 Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM) From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Sets New 52-Week High in Tuesday Session January 23, 2024 Via Investor Brand Network Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement January 16, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire 3 health care stocks off to strong starts in 2024 January 10, 2024 With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers. Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024 January 05, 2024 From Regeneron Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.